These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy. Senter PD FASEB J; 1990 Feb; 4(2):188-93. PubMed ID: 2404820 [TBL] [Abstract][Full Text] [Related]
6. Tumor-specific activation of prodrugs: is there a role for nuclear medicine? Antunes IF; Haisma HJ; de Vries EF Nucl Med Commun; 2008 Oct; 29(10):845-6. PubMed ID: 18769302 [No Abstract] [Full Text] [Related]
7. Antibody-directed enzyme prodrug therapy. Connors TA Cancer Cells; 1990 Feb; 2(2):56-7. PubMed ID: 2397145 [No Abstract] [Full Text] [Related]
8. Enzymatic cleavage of methotrexate provides a method for prevention of drug toxicity. Chabner BA; Johns DG; Bertino JR Nature; 1972 Oct; 239(5372):395-7. PubMed ID: 12635300 [No Abstract] [Full Text] [Related]
9. Antibody directed enzyme prodrug therapy (ADEPT). A review of some theoretical, experimental and clinical aspects. Bagshawe KD; Sharma SK; Springer CJ; Rogers GT Ann Oncol; 1994 Dec; 5(10):879-91. PubMed ID: 7696159 [TBL] [Abstract][Full Text] [Related]
11. Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. Springer CJ; Bagshawe KD; Sharma SK; Searle F; Boden JA; Antoniw P; Burke PJ; Rogers GT; Sherwood RF; Melton RG Eur J Cancer; 1991; 27(11):1361-6. PubMed ID: 1835849 [TBL] [Abstract][Full Text] [Related]
12. Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs. Springer CJ; Niculescu-Duvaz I Anticancer Drug Des; 1995 Jul; 10(5):361-72. PubMed ID: 7639927 [TBL] [Abstract][Full Text] [Related]
13. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. Springer CJ; Antoniw P; Bagshawe KD; Searle F; Bisset GM; Jarman M J Med Chem; 1990 Feb; 33(2):677-81. PubMed ID: 2299634 [TBL] [Abstract][Full Text] [Related]
14. Cyclosporine delays host immune response to antibody enzyme conjugate in ADEPT. Bagshawe KD; Sharma SK Transplant Proc; 1996 Dec; 28(6):3156-8. PubMed ID: 8962223 [No Abstract] [Full Text] [Related]
15. Development of prodrugs for enzyme-mediated, tumor-selective therapy. Yoon KJ; Potter PM; Danks MK Curr Med Chem Anticancer Agents; 2005 Mar; 5(2):107-13. PubMed ID: 15777218 [TBL] [Abstract][Full Text] [Related]
16. Targeting enzymes for cancer therapy: old enzymes in new roles. Deonarain MP; Epenetos AA Br J Cancer; 1994 Nov; 70(5):786-94. PubMed ID: 7947082 [TBL] [Abstract][Full Text] [Related]
17. Plasma clearance of an antibody--enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo. Rogers GT; Burke PJ; Sharma SK; Koodie R; Boden JA Br J Cancer; 1995 Dec; 72(6):1357-63. PubMed ID: 8519645 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine prodrugs for use in antibody-directed enzyme prodrug therapy. Masterson LA; Spanswick VJ; Hartley JA; Begent RH; Howard PW; Thurston DE Bioorg Med Chem Lett; 2006 Jan; 16(2):252-6. PubMed ID: 16290933 [TBL] [Abstract][Full Text] [Related]
19. Antibody directed enzyme prodrug therapy (ADEPT): a review of the experimental and clinical considerations. Syrigos KN; Epenetos AA Anticancer Res; 1999; 19(1A):605-13. PubMed ID: 10226606 [TBL] [Abstract][Full Text] [Related]
20. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Connors TA Gene Ther; 1995 Dec; 2(10):702-9. PubMed ID: 8750009 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]